This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Breast Cancer Awareness Month: One Woman's Story Underscores Importance Of Understanding Risk

Stocks in this article: GENE

ROGERS, Ark., Oct. 1, 2013 /PRNewswire/ -- At age 44, Cyndi Pierre believed that her family history of breast cancer – her mother and sister were both diagnosed – put her at risk for developing the disease, too. She ate healthy, exercised, and saw her doctor regularly for mammograms, which were normal. Pierre even tested negative for the BRCA "breast cancer" gene but, knowing that almost 80% of breast cancer cases are sporadic and involve little to no family history of the disease, she wanted to learn more.

To view the multimedia assets associated with this release, please click:

"I thought I had covered all my bases, but I couldn't shake this nagging feeling," Pierre said. "So I took the next step with the BREVAGen test. The results made it possible for me to get insurance coverage for a 3-D MRI, and I discovered I already had cancer. I feel that test saved my life."

In recognition of Breast Cancer Awareness Month, Phenogen Sciences Inc., a wholly owned subsidiary of Genetic Technologies Group (NASDAQ: GENE) and makers of the BREVAGen breast cancer predictive risk assessment test, congratulates Pierre for stepping forward as the first patient to acknowledge BREVAGen's role in saving her life from breast cancer. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer. To honor Pierre, the company has made a contribution to her fundraising efforts for the 31 st Susan G. Komen 3-Day for the Cure® 60-mile walk.

Pierre's story is one of determination and collaboration. After talking with her care team about doing everything she could to prevent breast cancer, Pierre's nurse practitioner suggested BREVAGen—a noninvasive DNA test that analyzes a woman's genetic and clinical risk factors to determine her risk of breast cancer. BREVAGen showed Pierre's risk was 33 percent—nearly three times higher than the average woman's. Cyndi's high score prompted her insurance company to approve a more sensitive 3-D MRI, which would give doctors a more detailed look at her breast health. That test detected a small lump in her left breast. It was cancer.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs